Loading…
Loading…
TACE (Trend Aggregation Conservative ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how TACE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TACE and 80,000+ other tickers.
This fund aims to generate a total return for investors. To achieve this, it strategically allocates capital to various exchange-traded funds (ETFs). These underlying ETFs predominantly focus on an eclectic mix of holdings, including debt instruments, real estate investment trusts (REITs), master limited partnerships (MLPs), income-generating equity stocks (such as those in the utility sector), put options, U.S. government bonds, and exchange-traded notes (ETNs). The fixed income ETFs within the portfolio are broad, encompassing both domestic and foreign bonds across the full spectrum of credit quality, maturity periods, and interest rate sensitivities.
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE), demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization. Patients in the investigational arms were tr.
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types PR Newswi
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
Shares of Trend Aggregation Conservative ETF (NYSEARCA:TACE - Get Free Report) dropped 0.2% on Tuesday. The stock traded as low as $25.55 and last traded at $25.59. Approximately 5,700 shares were traded during mid-day trading, a decline of 3% from the average daily volume of 5,895 shares. The stock had previously closed at $25.63.
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA in Combination With TACE Significantly Improved PFS Compared to TACE Alone in Patients With Unresectable, Non-Metastatic HCC.